Form 4: Jazz Pharma CCO Samantha Pearce Reports Share Activity

Jazz Pharmaceuticals' Chief Commercial Officer, Samantha Pearce, reported the acquisition of shares from performance awards and an employee stock purchase plan, alongside a tax-related disposition.

Summary

• Samantha Pearce, EVP, Chief Commercial Officer of Jazz Pharmaceuticals plc, reported changes in her beneficial ownership.
• On January 16, 2026, Pearce acquired 3,637 ordinary shares at a price of $0.0, resulting from the vesting of performance share awards granted on March 3, 2023.
• Concurrently, on January 16, 2026, 1,599 ordinary shares were disposed of at $171.16 per share to cover tax obligations related to the vesting of these performance share awards.
• Additionally, Pearce acquired 140 ordinary shares on November 28, 2025, through a Section 423 Employee Stock Purchase Plan.
• Following these transactions, Pearce beneficially owns 42,993 ordinary shares directly.

Sentiment

Score: 7

Explanation: The filing indicates a net increase in the executive's beneficial ownership due to the vesting of performance awards and an employee stock purchase plan, partially offset by shares withheld for tax obligations. This is a routine and generally positive sign of executive alignment with shareholder interests.

Positives

• Acquisition of 3,637 ordinary shares from performance awards indicates successful achievement of performance-based vesting requirements.
• Acquisition of 140 ordinary shares through an Employee Stock Purchase Plan demonstrates continued investment in the company by an executive.
• The net increase in shares (3,637 + 140 1,599 = 2,178 shares) indicates a positive change in beneficial ownership.

Negatives

• Disposition of 1,599 ordinary shares to satisfy tax obligations, though a common practice, reduces direct beneficial ownership.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions for an executive at a pharmaceutical company. Such filings are common and reflect standard executive compensation practices, including performance-based equity awards and employee stock purchase plans, which are prevalent across the biopharmaceutical industry.

Stakeholder Impact

• Shareholders: The net increase in executive ownership aligns executive interests with shareholders.
• Employees: The Employee Stock Purchase Plan indicates a benefit available to employees (or at least executives).

Key Dates

Recommendation

This Form 4 details routine, non-discretionary insider transactions related to executive compensation (performance share vesting and tax withholding) and an employee stock purchase plan. While the net increase in shares is a positive signal of executive alignment, these transactions are not indicative of new strategic developments or a change in the company's fundamental outlook. Therefore, the filing itself does not warrant a change in investment recommendation; a 'hold' stance is appropriate based solely on this information, pending further fundamental analysis.

Keywords

Jazz Pharmaceuticals, JAZZ, Samantha Pearce, Insider Trading, Form 4, Stock Award, Performance Shares, Employee Stock Purchase Plan, Executive Compensation, Beneficial Ownership